Table 5.

Lipids, apoAI, apoB level and lipid and lipoprotein ratios in the control group and patients with apoAI ≥150 mg/dL, apoAI ≤150 mg/dL and all patients with CAP, median (min- max)

	Control group	Patients with apoAI ≥150 mg/dl	Patients with apoAI ≤ 150 mg/dl	All patients
	n = 20	n = 18	n = 25	n = 43
TG (mmol/L)	1.07(0.70–1.94)	1.27(0.58–1.84)	1.45(0.65–4.26)	1.33(0.58–4.26)
TC (mmol/L)	4.92(4.35–5.69)	5.49(4.19–7.20)	5.28(3.80–7.40)	5.38(3.80–7.40)
LDL-C (mmol/L)	3.15(2.20–3.62)	4.04(2.20–4.71)	3.72(2.14–5.23)	3.78(2.14–5.23)
HDL-C (mmol/L)	1.42(1.13–2.40)	1.52(1.19–2.07)	1.08(0.49–1.50)*,***	1.16(0.49–2.07)
nHDL-C (mmol/L)	3.62(2.53–4.19)	4.06(2.53–5.23)	4.35-(2.64–6.21)	3.93(2.64–6.21)
apoAI (g/L)	1680(1500–2030)	1740(1500–2350)	1340(790–1480)*,***	1440(790–2350)
apoB (g/L)	880(620–1060)	760(520–1280)	86(0500–1490)	870(500–1490)
TC/HDL-C	3.45(2.17–4.45)	3.58(2.56–4.82)	4.92(2.68–9.27)*	4.63(2.56–9.27)*
LDL/HDL-C	2.22(1.11–3.72)	2.64(1.35–3.54)	3.50(1.80–9.53)*	3.24(1.35–9.53)*
TG/HDL-C	1.72(1.0–3.2)	1.91(0.72–3.26)	3.09(1.07–11.82)*	2.56(0.72–11.82)*
HDL-C/apoAI	0.33(0.32–0.47)	0.33(0.27–0.51)	0.31(0.16–0.66)	0.31(0.16–0.66)
apoAI/apoB	1.89(1.17–3.27)	2.28(1.36–3.27)	1.56(0.70–2.55)*	1.65(0.70–3.17)

p < 0.05-*- vs control group

p < 0.05-*** - vs apoAI ≥ 150 mg/dl